U.S. markets open in 3 hours 25 minutes
  • S&P Futures

    4,160.75
    -4.00 (-0.10%)
     
  • Dow Futures

    34,005.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    13,908.50
    -10.75 (-0.08%)
     
  • Russell 2000 Futures

    2,229.40
    -9.00 (-0.40%)
     
  • Crude Oil

    61.06
    -0.29 (-0.47%)
     
  • Gold

    1,787.40
    -5.70 (-0.32%)
     
  • Silver

    26.39
    -0.18 (-0.68%)
     
  • EUR/USD

    1.2051
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.5640
    0.0000 (0.00%)
     
  • Vix

    17.29
    -1.39 (-7.44%)
     
  • GBP/USD

    1.3909
    -0.0023 (-0.16%)
     
  • USD/JPY

    108.0210
    -0.0220 (-0.02%)
     
  • BTC-USD

    54,228.00
    -1,148.58 (-2.07%)
     
  • CMC Crypto 200

    1,255.08
    -7.88 (-0.62%)
     
  • FTSE 100

    6,909.27
    +13.98 (+0.20%)
     
  • Nikkei 225

    29,188.17
    +679.62 (+2.38%)
     

Why Earnings Season Could Be Great for Health Catalyst (HCAT)?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors are always looking for stocks that are poised to beat at earnings season and Health Catalyst, Inc. HCAT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Health Catalyst is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for HCAT in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 23 cents cents per share for HCAT, compared to a broader Zacks Consensus Estimate of a loss of 24 cents per share. This suggests that analysts have very recently bumped up their estimates for HCAT, giving the stock a Zacks Earnings ESP of +5.48% heading into earnings season.

Health Catalyst, Inc. Price and EPS Surprise

Health Catalyst, Inc. Price and EPS Surprise
Health Catalyst, Inc. Price and EPS Surprise

Health Catalyst, Inc. price-eps-surprise | Health Catalyst, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that HCAT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Health Catalyst, and that a beat might be in the cards for the upcoming report.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Health Catalyst, Inc. (HCAT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.